Panelists discuss how insurance challenges impact spinal muscular atrophy (SMA) care, with prior authorizations becoming more streamlined over time but limitations on physical therapy sessions and inequitable access to treatments remain significant barriers.
Clinical Brief: Insurance Challenges in SMA Treatment
Main Discussion Topics
Key Points for Physicians
Notable Insights
The panel highlighted the paradox that evaluations to demonstrate treatment efficacy count against patients' limited therapy session allowances, forcing difficult choices between assessment and actual therapeutic intervention.
Clinical Significance
Advocacy for comprehensive coverage of disease-modifying therapies and supportive services is essential, with emphasis on long-term benefits, including improved quality of life, reduced hospitalizations, and increased workforce participation.
RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis
June 19th 2025Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Read More